source
- PepGen's Phase 2 DM1 Data Show 46% Average Splicing Correction, Shares Jump 163%PepGen reported results from the 10 mg/kg multiple‑ascending‑dose cohort of its ongoing Phase 2 Freedom2‑DM1 trial, testing PGN‑EDODM1, an oligonucleotide designed to correct the molecular defect i…
- Intersurgical pulls 22mm smoothbore breathing tubes after FDA warns of detaching connectorsThe FDA Center for Devices and Radiological Health issued an early alert about a potentially high‑risk issue with certain Intersurgical breathing devices. Intersurgical has sent a letter to custom…